RAS, SOS1 & SHP2 Inhibitors | Approved Therapies & Global Pipeline

Last Update: Aug 25, 2023

Purchase the complete database including drugs in pre-clinical development (30+ rows), discontinued programs and quarterly US and ex-US sales of Lumakras/Lumykras.


Approved Therapies

Company Product MOA Indications Approval
AmgenLUMAKRAS/LUMYKRAS (sotorasib)KRAS G12C inhibitorKRAS G12C-mutated locally advanced or metastatic NSCLC05/21 (US) 01/22 (EU)
Mirati TherapeuticsKRAZATI (adagrasib)KRAS G12C inhibitor2L KRAS G12C-mutated locally advanced or metastatic NSCLC12/22 (US)

RAS inhibitors & RAS-targeting drugs

Company Candidate MOA Indications Phase
AmgenSotorasib (AMG 510)KRAS G12C inhibitorKRAS G12C-mutant NSCLC, advanced CRC, pancreatic and other solid tumorsIII
MiratiAdagrasib (MRTX849)KRAS G12C inhibitorKRAS G12C-mutant NSCLC, CRC, pancreaticIII
NovartisJDQ443KRAS G12C inhibitorKRAS G12C-mutant solid tumors (┬▒TNO155 & spartalizumab)III
Inventisbio/Chia-Tai TianqingD-1553KRAS G12C inhibitorKRAS G12C-mutant NSCLC, CRC, other tumors (monotherapy+combination)II
Genentech (Roche)Divarasib (GDC-6036)KRAS G12C inhibitorKRAS G12C-mutant NSCLC, CRC, advanced solid tumorsIb/II
ModernamRNA-5671KRAS vaccineNSCLC, CRC, advanced solid tumorsI
Revolution MedicinesRMC-6236Multi-RAS(ON) (H-,K-,N-) inhibitorKRAS-mutant advanced solid tumorsI/Ib
Jacobio PharmaJAB-21822KRAS G12C inhibitorKRAS G12C-mutant NSCLC, CRC, advanced solid tumorsI/II
Innovent BiologicsIBI351 (GFH925)KRAS G12C inhibitorKRAS G12C-mutant NSCLC, CRC, advanced solid tumorsI
Eli LillyLY3537982KRAS G12C inhibitorKRAS G12C-mutant advanced solid tumorsIa/Ib
Elicio TherapeuticsELI-002KRAS vaccine with AMPKRAS-mutated PDAC and other solid tumorsI
Alaunos TherapeuticsTCR-T LibraryNeoantigen-specific TCR T cell (KRAS G12D)KRAS-mutant solid tumorsI
Astellas PharmaASP3082KRAS G12D PROTACKRAS G12D mutant solid tumorsI
Revolution MedicinesRMC-6291K/NRAS G12C (ON)KRAS G12C-mutant cancersI/Ib
ImmuneeringIMM-1-104Dual MEK 1/2 inhibitor/pan-KRAS/NRASRAS-mutant advanced or metastatic solid tumorsI/IIa
ErascaERAS-3490KRAS G12C inhibitorKRAS G12C-mutant solid tumorsI

SOS1 inhibitors

Company Candidate MOA Indications Phase
Boehringer (Lupin)BI 1701963SOS1 inhibitorKRAS-mutant cancer w/ Adagrasib or MEK inhibitor (Trametinib)I/Ib
MiratiMRTX0902SOS1 inhibitorCombination with KRAS inhibitor (adagrasib)I/II

SHP2 inhibitors

Company Candidate MOA Indications Phase
Revolution MedicinesRMC-4630SHP2 inhibitorRTK cancers (+-MEKi, +- sotorasib, +- LY3214996 +- pembrolizumab, +-adagrasib)Ib/II
NovartisTNO155SHP2 inhibitorKRAS-mutant cancers (combination trials), BRAF V600 CRC, Hepatic impairmentI/II
Bristol Myers Squibb & BridgeBioBBP-398SHP2 inhibitorRTK cancers (KRAS-mutant NSCLC +nivolumab or +sotorasib), EGFRm advanced solid tumorsIb
Relay Therapeutics & GenentechRLY-1971 (GDC-1971)SHP2 inhibitorRTK cancers (advanced or metastatic solid tumors +- atezolizumab +- GDC-6036)Ib
PfizerPF-07284892 (ARRY-558)SHP2 inhibitorRTK cancers (BRAF V600E, RASm, ALK+) +- encorafenib, +- cetuximabI
AbbVieJAB-3312SHP2 inhibitorRTK cancers +- MEKi, +- anti-PD1, +- KRAS G12Ci (JAB-21822)I/IIa
ErascaERAS-601SHP2 inhibitorRAS/MAPK-altered advanced or metastatic solid tumors (+- cetuximab +- ERAS-007 +- sotorasib)I/II
HUYA bioscienceHBI-2376SHP2 inhibitorKRAS/EGFR-mutant advanced or metastatic solid tumorsI
Nanjing SanhomeSH3809SHP2 inhibitorAdvanced solid tumorsI
Etern TherapeuticsET0038SHP2 inhibitorAdvanced solid tumors (+pembrolizumab)I
Betta Pharmaceuticals (Xcovery)BPI-442096SHP2 inhibitorAdvanced solid tumors (NSCLC, CRC, pancreatic)I


FULL DATABASE